Kalaris Therapeutics Inc
NASDAQ:KLRSBiotechnology
+$0.16 today
- Market cap
- $54.75M
- Beta
- 0.14
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$1.86
Volume 0.07M
Average 0.08M
KLRS Total Current Liabilities
All obligations due within one year.
Kalaris Therapeutics IncNASDAQ: KLRS
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 13.1% from a year ago
Total current liabilities stood at $8.08M at the end of Q1 FY2026, up 13.1% from a year earlier and down 16.8% from the prior quarter. Over 3 fiscal years it compounded at +19.5% a year.
Context
- Total current liabilities amounted to 7.4% of total assets at the end of Q1 FY2026, up 0.4 pp from a year earlier.
- Total current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +13.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 9.71M USD
- Year-over-year change
- +85.4%
- 4-year CAGR
- -28.8%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.71M | +85.4% |
| FY2024 | 2024-12-31 | 5.24M | +32.9% |
| FY2023 | 2023-12-31 | 3.94M | -30.7% |
| FY2022 | 2022-12-31 | 5.69M | -85.0% |
| FY2021 | 2021-12-31 | 37.85M | — |
Total Current Liabilities vs competitors
How KLRS compares with its peers on the latest reported figures
- Peers report in different currencies, so total current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +13.1% is the 4th highest of 9, against a peer median of -17.7%.
- Total current liabilities amounts to 7.4% of total assets for KLRS, versus a peer median of 10.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $70.81M USD | -46.8% | +4.1% | 29.3% | |
| Mar 2026 | $15.75M USD | +69.2% | +5.8% | 7.0% | |
| Dec 2025 | $13.61M USD | +60.9% | -4.5% | 24.3% | |
| Mar 2026 | €11.4M EUR | -29.6% | -0.1% | 23.3% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $10.88M USD | -10.8% | -20.1% | 10.3% |
KLRSKalaris Therapeutics Inc | Mar 2026 | $8.08M USD | +13.1% | +19.5% | 7.4% |
IMAImageneBio Inc | Mar 2026 | $6.63M USD | -24.6% | -19.5% | 4.9% |
| Mar 2026 | $6.53M USD | +243.9% | +35.7% | 11.1% | |
| Mar 2026 | $4.25M USD | -41.9% | -34.4% | 4.2% | |
| Peer median (excluding KLRS) | — | -17.7% | -2.3% | 10.7% | |
Competitors are the stored peer set for KLRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 201.66M | 3.06M | 3.17M | 118.29M | 98.05M |
| Short-term Investments | 46.46M | 0 | 0 | 0 | 19.93M |
| Net Receivables | 50K | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 5.18M | 3K | 17K | 257K | 78K |
| Total Current Assets | 253.35M | 3.9M | 3.33M | 118.55M | 118.81M |
| Property, Plant & Equipment (Net) | 31.29M | 0 | 0 | 0 | 1.48M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 852K | 0 | 0 | 0 | 499K |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.1M | 0 | 0 | 0 | 953K |
| Total Non-current Assets | 33.25M | 0 | 0 | 0 | 2.93M |
| Total Assets | 286.59M | 3.9M | 3.33M | 118.55M | 121.74M |
| Account Payables | 8.36M | 2.76M | 2.36M | 247K | 1.28M |
| Short-term Debt | 6.59M | 0 | 0 | 0 | 316K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 15.03M | 296K | 540K | 1.96M | 6.52M |
| Total Current Liabilities | 37.85M | 5.69M | 3.94M | 5.24M | 9.71M |
| Long-term Debt | 0 | 3.25M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 25.23M | 44.41M | 0 | 32.08M |
| Total Non-current Liabilities | 23.48M | 28.48M | 44.41M | 0 | 33.21M |
| Total Liabilities | 61.33M | 34.17M | 48.35M | 5.24M | 42.92M |
| Common Stock | 7K | 0 | 0 | 0 | 2K |
| Retained Earnings | (297.07M) | (32.7M) | (47.39M) | (714.96M) | (160M) |
| Accumulated OCI | (155K) | 0 | 0 | (135K) | 6K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 225.27M | (30.27M) | (45.02M) | 113.31M | 78.81M |
| Total Debt | 30.07M | 3.25M | 0 | 0 | 1.45M |
| Net Debt | (171.6M) | 194K | (3.17M) | (118.29M) | (96.61M) |
Kalaris Therapeutics Inc
NASDAQ:KLRS
Intrinsic Alpha fair value
Locked
Current Price
$2.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.